Preexisting Antibodies in Patients Treated With Anti–PD-1 for Advanced Non–Small Cell Lung Cancer

Leggi l'articolo originale


This medical records analysis from a single institution in Japan assesses anti–PD-1 treatment in patients with subclinical advanced non–small cell lung cancer and with or without preexisting autoimmune markers and evaluates potential clinical biomarkers that may be associated with clinical benefit or with immune-related adverse events.

Lascia un commento